![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB |
![[thumbnail of Supplemental Materials]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplemental Materials)
1MB |
| Item Type: | Article |
|---|---|
| Title: | The frequency of differentiated CD3(+)CD27(-)CD28(-) T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma |
| Creators Name: | Worel, N., Grabmeier-Pfistershammer, K., Kratzer, B., Schlager, M., Tanzmann, A., Rottal, A., Körmöczi, U., Porpaczy, E., Staber, P.B., Skrabs, C., Herkner, H., Gudipati, V., Huppa, J.B., Salzer, B., Lehner, M., Saxenhuber, N., Friedberg, E., Wohlfarth, P., Hopfinger, G., Rabitsch, W., Simonitsch-Klupp, I., Jäger, U. and Pickl, W.F. |
| Abstract: | BACKGROUND: Chimeric antigen receptor T (CART) cell therapy targeting the B cell specific differentiation antigen CD19 has shown clinical efficacy in a subset of relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL) patients. Despite this heterogeneous response, blood pre-infusion biomarkers predicting responsiveness to CART cell therapy are currently understudied. METHODS: Blood cell and serum markers, along with clinical data of DLBCL patients who were scheduled for CART cell therapy were evaluated to search for biomarkers predicting CART cell responsiveness. FINDINGS: Compared to healthy controls (n=24), DLBCL patients (n=33) showed significant lymphopenia, due to low CD3(+)CD4(+) T helper and CD3(-)CD56(+) NK cell counts, while cytotoxic CD3(+)CD8(+) T cell counts were similar. Although lymphopenic, DLBCL patients had significantly more activated HLA-DR(+) (P=0.005) blood T cells and a higher frequency of differentiated CD3(+)CD27(-)CD28(-) (28.7 ± 19.0% versus 6.6 ± 5.8%; P<0.001) T cells. Twenty-six patients were infused with CART cells (median 81 days after leukapheresis) and were analyzed for the overall response (OR) 3 months later. Univariate and multivariate regression analyses showed that low levels of differentiated CD3(+)CD27(-)CD28(-) T cells (23.3 ± 19.3% versus 35.1 ± 18.0%) were independently associated with OR. This association was even more pronounced when patients were stratified for complete remission (CR versus non-CR: 13.7 ± 11.7% versus 37.7 ± 17.4%, P=0.001). A cut-off value of = 18% of CD3(+)CD27(-)CD28(-) T cells predicted CR at 12 months with high accuracy (P<0.001). In vitro, CD3(+)CD8(+)CD27(-)CD28(-) compared to CD3(+)CD8(+)CD27(+)CD28(+) CART cells displayed similar CD19(+) target cell-specific cytotoxicity, but were hypoproliferative and produced less cytotoxic cytokines (IFN-? and TNF-a). CD3(+)CD8(+) T cells outperformed CD3(+)CD4(+) T cells 3- to 6-fold in terms of their ability to kill CD19(+) target cells. INTERPRETATION: Low frequency of differentiated CD3(+)CD27(-)CD28(-) T cells at leukapheresis represents a novel pre-infusion blood biomarker predicting a favorable response to CART cell treatment in r/r DLBCL patients. |
| Keywords: | Diffuse Large B Cell Lymphoma, Chimeric Antigen Receptor T Cells Therapy, CD27, CD28, Biomarker |
| Source: | Frontiers in Immunology |
| ISSN: | 1664-3224 |
| Publisher: | Frontiers Media SA |
| Volume: | 13 |
| Page Range: | 1004703 |
| Date: | 9 January 2022 |
| Official Publication: | https://doi.org/10.3389/fimmu.2022.1004703 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
